| |
|
|
| |
Inhaled CNS Therapeutics
Drugs, Devices, Diseases, Targets, and
Therapeutics
|
Publication: May 2012
Product Code: PCNS333K
|
Delivering drugs to the central nervous system presents
unique challenges. But, drug developers and researchers have
discovered that delivering CNS therapeutic drugs via
inhalation mitigates several of these issues. The
accessibility and vascular structure of the nose make it an
attractive route for delivering both small molecule drugs
and biologics across the blood-brain barrier to the CNS.
Pulmonary delivery to the deep lung can have favorable
pharmacokinetics. And inhaled delivery offers the potential
for faster onset of action and less frequent dosing relative
to oral drugs. These potential advantages have spurred
activity in inhaled CNS therapeutics for a range of
disorders. As aging population demographics and managed care
initiatives drive growth in home health care and
self-administration of drug therapies, inhaled medicine is
increasingly being viewed as patient-friendly and
cost-effective. |
|
Highlights |
· Analyzes and evaluates
systemic inhaled drug therapeutics for CNS disorders and
diseases and assesses the market potential for existing
and probable future products
· Provides detailed
assessments of CNS therapeutic market segments, market
demographics, and business strategies
· Charts product sales
data, market share, and forecasts to 2016
· Profiles sector
companies, their product development activities,
business strategies, and corporate alliances and
affiliations
· Evaluates the impact of
economic, technology, and regulatory
factors on Inhaled CNS Therapeutics
|
|
Summary of Contents |
Executive Summary
Drug Delivery Market
Dynamics
The Trend toward Self-Administration
Demographic Shifts
Managed Care Initiatives
Growth in Home Healthcare
Technology Market
Drivers
CNS Therapeutic Sector Assessment
Alzheimer’s
ADHD
Autism
Dementia
Depression
Epilepsy
Migraine
Multiple
Sclerosis
Nausea
Pain Management
Parkinson’s
Schizophrenia
Sleeping disorders
Stroke
Inhaled Drug Development Factors
Absorption
Bioavailability
Device Design
Parameters
Nasal Delivery Pharmacokinetics
Nasal Device Characteristics
Pulmonary Delivery
Pharmacokinetics
Pulmonary Device Characteristics
Market Factors
FDA Regulations
Clinical Trials
Impact of Generics
FDA-Approved Inhaled CNS Drug Products
|
|
|
|
|
